Post-Dilation of Self-Expanding Valves: Frequency, Usefulness, and Risks

Post-Dilation of Self-Expanding ValvesThis study explores the impact of balloon post-dilation on studies conducted in the United States assessing the CoreValve self-expandable valve.

 

Procedural details of 3532 patients were examined to determine whether post-dilation was performed after valve implantation. Best practice guidelines recommend post-dilation to improve suboptimal outcomes, being the most frequent alternative for treating moderate or severe paravalvular insufficiency.

 

Post-dilation was performed in 782 patients (22%); the most common (58.1%) indication was greater than or equal to moderate paravalvular insufficiency. 

 

Predictors for the need for post-dilation were the following:

  • Baseline transvalvular gradients (p <0.001)
  • Higher baseline aortic insufficiency (p <0.001)
  • Larger annular diameter (p <0.001)
  • Lower device (p <0.001)

 

Post-dilation was significantly less frequent with the 26-mm devices (17.9%) compared to the 31-mm devices (38.1%).

 

Post-dilation effectively reduced moderate or severe aortic insufficiency by around 75.6% (from 58.1% to 14.2%).

 

Clinical outcomes at 30 days and 1 year were similar in both groups, except for a higher rate of acute kidney insufficiency in patients who underwent post-dilation (p = 0.026), which could be explained by the additional aortography necessary for control.

 

The rate of major adverse cardiovascular and cerebrovascular events was 9.3% in the post-dilation group and 7.5% for other patients (p = ns). There was no increase in neurological events.

 

Conclusion

Post-dilation was performed in 22% of patients receiving a CoreValve valve, most frequently due to a need to reduce the degree of residual paravalvular aortic insufficiency. Post-dilation effectively and immediately improved outcomes and was not associated with an increase in neurological events.

 

Original title: Balloon Post-Dilation Following Implantation of a Self-Expanding Transcatheter Aortic Valve Bioprosthesis.

Reference: J. Kevin Harrison et al. J Am Coll Cardiol Intv 2017;10:168-75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...